Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

A broader strategy for osteoporosis interventions.

Reid IR.

Nat Rev Endocrinol. 2020 Mar 17. doi: 10.1038/s41574-020-0339-7. [Epub ahead of print] Review.

PMID:
32203407
2.

Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial.

Grey A, Horne A, Gamble G, Mihov B, Reid IR, Bolland AM.

J Clin Endocrinol Metab. 2020 Apr 1;105(4). pii: dgaa062. doi: 10.1210/clinem/dgaa062.

PMID:
32016386
3.

Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.

Reid IR, Horne AM, Mihov B, Stewart A, Bastin S, Gamble GD.

Calcif Tissue Int. 2020 Apr;106(4):386-391. doi: 10.1007/s00223-019-00653-7. Epub 2020 Jan 2.

PMID:
31897528
4.

Management of Paget's disease of bone.

Reid IR.

Osteoporos Int. 2019 Dec 17. doi: 10.1007/s00198-019-05259-1. [Epub ahead of print] Review.

PMID:
31848640
5.

Calcium and Bone.

Reid IR, Bristow SM.

Handb Exp Pharmacol. 2019 Dec 3. doi: 10.1007/164_2019_324. [Epub ahead of print]

PMID:
31792679
6.

Controversies in medicine: the role of calcium and vitamin D supplements in adults.

Reid IR, Bolland MJ.

Med J Aust. 2019 Nov;211(10):468-473. doi: 10.5694/mja2.50393. Epub 2019 Nov 3. Review.

PMID:
31680267
7.

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.

McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators.

Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31.

PMID:
31676222
8.

Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD.

J Bone Miner Res. 2020 Jan;35(1):20-27. doi: 10.1002/jbmr.3860. Epub 2019 Oct 11.

PMID:
31603996
9.

Recent advances in understanding and managing Paget's disease.

Reid IR.

F1000Res. 2019 Aug 22;8. pii: F1000 Faculty Rev-1485. doi: 10.12688/f1000research.19676.1. eCollection 2019. Review.

10.

Bisphosphonates for Prevention of Bone Loss in Glucocorticoid-Treated Young People.

Reid IR.

EClinicalMedicine. 2019 Jul 12;12:8-9. doi: 10.1016/j.eclinm.2019.07.002. eCollection 2019 Jul. No abstract available.

11.

Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.

Park YE, Bava U, Lin JM, Cornish J, Naot D, Reid IR.

Calcif Tissue Int. 2019 Nov;105(5):497-505. doi: 10.1007/s00223-019-00590-5. Epub 2019 Jul 19.

PMID:
31324954
12.

Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.

Bolland MJ, Horne AM, Briggs SE, Thomas MG, Reid IR, Gamble GD, Grey A.

Calcif Tissue Int. 2019 Oct;105(4):423-429. doi: 10.1007/s00223-019-00579-0. Epub 2019 Jun 27.

PMID:
31250043
13.

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.

Horne AM, Mihov B, Reid IR.

Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17. No abstract available.

PMID:
31087124
14.

Fibroblast growth factor 23 levels decline following sleeve gastrectomy.

Billington EO, Murphy R, Gamble GD, Callon K, Davies N, Plank LD, Booth M, Reid IR.

Clin Endocrinol (Oxf). 2019 Jul;91(1):87-93. doi: 10.1111/cen.13981. Epub 2019 Apr 15.

PMID:
30943313
15.

Fracture Prevention with Zoledronate in Older Women with Osteopenia. Reply.

Reid IR, Horne AM, Gamble GD.

N Engl J Med. 2019 Mar 28;380(13):1288. doi: 10.1056/NEJMc1900923. No abstract available.

PMID:
30917270
16.

Dietary Calcium Intake and Bone Loss Over 6 Years in Osteopenic Postmenopausal Women.

Bristow SM, Horne AM, Gamble GD, Mihov B, Stewart A, Reid IR.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3576-3584. doi: 10.1210/jc.2019-00111.

PMID:
30896743
17.

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wiessing KR, Bolland MJ, Bastin S, Gamble GD.

J Intern Med. 2019 Aug;286(2):221-229. doi: 10.1111/joim.12901. Epub 2019 Apr 8.

PMID:
30887607
18.
19.

Fracture Prevention with Zoledronate in Older Women with Osteopenia.

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD.

N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082. Epub 2018 Oct 1.

PMID:
30575489
20.

High-dose vitamin D: Without benefit but not without risk.

Reid IR.

J Intern Med. 2018 Dec;284(6):694-696. doi: 10.1111/joim.12836. Epub 2018 Oct 14. No abstract available.

PMID:
30230641
21.

Calcium and vitamin D: To supplement or not?

Reid IR.

Cleve Clin J Med. 2018 Sep;85(9):693-698. doi: 10.3949/ccjm.85a.18026. No abstract available.

22.

Effects of Leptin on the Skeleton.

Reid IR, Baldock PA, Cornish J.

Endocr Rev. 2018 Dec 1;39(6):938-959. doi: 10.1210/er.2017-00226. Review.

PMID:
30184053
23.

Calcium and vitamin D do not prevent fractures in community-dwelling adults.

Reid IR.

BMJ Evid Based Med. 2018 Oct;23(5):185-186. doi: 10.1136/bmjebm-2018-110974. Epub 2018 Jun 21. Review. No abstract available.

PMID:
29930018
24.

Denosumab for glucocorticoid-induced osteoporosis.

Reid IR.

Nat Rev Endocrinol. 2018 Jul;14(7):383-384. doi: 10.1038/s41574-018-0035-z. No abstract available.

PMID:
29849116
25.

25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density: Secondary Analysis of a Randomized Controlled Trial.

Macdonald HM, Reid IR, Gamble GD, Fraser WD, Tang JC, Wood AD.

J Bone Miner Res. 2018 Aug;33(8):1464-1469. doi: 10.1002/jbmr.3442. Epub 2018 Jun 15.

26.

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.

Horne AM, Mihov B, Reid IR.

Calcif Tissue Int. 2018 Jul;103(1):55-61. doi: 10.1007/s00223-018-0404-6. Epub 2018 Feb 14.

PMID:
29445836
27.

Vitamin D Effect on Bone Mineral Density and Fractures.

Reid IR.

Endocrinol Metab Clin North Am. 2017 Dec;46(4):935-945. doi: 10.1016/j.ecl.2017.07.005. Epub 2017 Sep 29. Review.

PMID:
29080644
28.

Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study.

Dalbeth N, Pool B, Chhana A, Lin JM, Tay ML, Tan P, Callon KE, Naot D, Horne A, Drake J, Gamble GD, Reid IR, Grey A, Stamp LK, Cornish J.

Calcif Tissue Int. 2018 Jan;102(1):73-84. doi: 10.1007/s00223-017-0328-6. Epub 2017 Oct 10.

PMID:
29018897
29.

Calcium and Cardiovascular Disease.

Reid IR, Birstow SM, Bolland MJ.

Endocrinol Metab (Seoul). 2017 Sep;32(3):339-349. doi: 10.3803/EnM.2017.32.3.339. Review.

30.

Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.

Grey A, Bolland MJ, Horne A, Mihov B, Gamble G, Reid IR.

CMAJ. 2017 Sep 11;189(36):E1130-E1136. doi: 10.1503/cmaj.161207.

31.

Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial.

Reid IR, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Singh M, Taylor L, Fenwick S, Camargo CA, Stewart AW, Scragg R.

J Intern Med. 2017 Nov;282(5):452-460. doi: 10.1111/joim.12651. Epub 2017 Jul 26.

32.

Are more trials of calcium supplements really needed?

Bolland MJ, Grey A, Reid IR.

Osteoporos Int. 2017 Sep;28(9):2729-2730. doi: 10.1007/s00198-017-3988-1. Epub 2017 Jul 7. No abstract available.

PMID:
28687861
33.

Dietary calcium intake and rate of bone loss in men.

Bristow SM, Gamble GD, Horne AM, Reid IR.

Br J Nutr. 2017 May;117(10):1432-1438. doi: 10.1017/S0007114517001301. Epub 2017 Jun 13.

PMID:
28606219
34.

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

Reid IR.

BioDrugs. 2017 Aug;31(4):289-297. doi: 10.1007/s40259-017-0229-2. Review.

PMID:
28547661
35.

Serum phosphate is related to adiposity in healthy adults.

Billington EO, Gamble GD, Bristow S, Reid IR.

Eur J Clin Invest. 2017 Jul;47(7):486-493. doi: 10.1111/eci.12769. Epub 2017 Jun 13.

PMID:
28517037
36.

Bone Loss After Denosumab: Only Partial Protection with Zoledronate.

Reid IR, Horne AM, Mihov B, Gamble GD.

Calcif Tissue Int. 2017 Oct;101(4):371-374. doi: 10.1007/s00223-017-0288-x. Epub 2017 May 13.

PMID:
28500448
37.

Calcium Intake and Cardiovascular Disease Risk.

Reid IR, Avenell A, Grey A, Bolland MJ.

Ann Intern Med. 2017 May 2;166(9):684-685. doi: 10.7326/L17-0135. No abstract available.

PMID:
28460389
38.

Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.

Reid IR, Maslowski K.

Calcif Tissue Int. 2017 Jul;101(1):43-49. doi: 10.1007/s00223-017-0261-8. Epub 2017 Mar 21.

PMID:
28324123
39.

Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.

Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR.

Osteoporos Int. 2017 Jun;28(6):1867-1874. doi: 10.1007/s00198-017-3960-0. Epub 2017 Feb 23.

PMID:
28233020
40.

Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Billington EO, Gamble GD, Reid IR.

Bonekey Rep. 2016 Dec 7;5:852. doi: 10.1038/bonekey.2016.85. eCollection 2016.

41.

Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.

Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw.

J Clin Densitom. 2017 Jan - Mar;20(1):8-24. doi: 10.1016/j.jocd.2016.09.005. Epub 2016 Dec 9. Review.

PMID:
27956123
42.

Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone.

Reid IR, Wattie D, Gamble GD, Kalluru R, Cundy T.

Calcif Tissue Int. 2017 Mar;100(3):250-254. doi: 10.1007/s00223-016-0214-7. Epub 2016 Nov 19.

PMID:
27866237
43.

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.

Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, Brown TD, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, Jan De Beur S, Kagan R, Kiel DP, Reid IR, Solomon DH, Randall S.

J Bone Miner Res. 2017 Jan;32(1):3-10. doi: 10.1002/jbmr.3039. Epub 2016 Dec 27.

44.

Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone.

Cundy T, Maslowski K, Grey A, Reid IR.

J Bone Miner Res. 2017 Apr;32(4):753-756. doi: 10.1002/jbmr.3029. Epub 2016 Nov 30.

45.

Postmenopausal osteoporosis.

Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR.

Nat Rev Dis Primers. 2016 Sep 29;2:16069. doi: 10.1038/nrdp.2016.69. Review.

PMID:
27681935
46.

Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention.

Avenell A, Bolland MJ, Grey A, Reid IR.

Osteoporos Int. 2017 Feb;28(2):733-734. doi: 10.1007/s00198-016-3765-6. Epub 2016 Sep 19. No abstract available.

PMID:
27647527
47.

Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women.

Billington EO, Bristow SM, Gamble GD, de Kwant JA, Stewart A, Mihov BV, Horne AM, Reid IR.

Osteoporos Int. 2017 Jan;28(1):119-125. doi: 10.1007/s00198-016-3744-y. Epub 2016 Aug 20.

PMID:
27543500
48.

Controversies in osteoporosis management.

Reid IR.

Intern Med J. 2016 Jul;46(7):767-70. doi: 10.1111/imj.13131. No abstract available.

PMID:
27405889
49.

Vitamin D supplements do not prevent falls.

Bolland MJ, Grey A, Reid IR.

BMJ. 2016 Jun 1;353:i3005. doi: 10.1136/bmj.i3005. No abstract available.

PMID:
27250717
50.

Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.

Reid IR, Sharma S, Kalluru R, Eagleton C.

Calcif Tissue Int. 2016 Sep;99(3):322-5. doi: 10.1007/s00223-016-0150-6. Epub 2016 May 18. Review.

PMID:
27193832

Supplemental Content

Support Center